Jubilant Life Sciences yesterday posted a consolidated net loss of Rs 94.11 crore for the second quarter ended September 30, 2014. The company had posted a net loss of Rs 80.58 crore during the same period of previous fiscal.
Reacting to the muted earnings, shares of the company opened at Rs 153, then fell as much as 12.64 per cent to touch an intra-day low of Rs 144. At the end of trading session, the stock closed at Rs 146.80, down 10.96 per cent on the BSE.
Market experts said that the downtrend in the counter was largely on the back of weak earnings.
The company's net sales in the quarter under review stood at Rs 1,362.11 crore during the period, down 4.36 per cent compared to Rs 1,424.3 crore in the same period previous fiscal.
Overall expenses of the company went up by 7.56 per cent to Rs 1,329.29 crore in Q2 of FY'15 against Rs 1,235.75 crore in the Q2 of FY'14.
During the quarter under review, revenue of pharmaceuticals segment declined 11.34 per cent to Rs 614.30 crore, while revenue from life science ingredients segment went up by 1.67 per cent to Rs 756.8 crore.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
